ANTITUBERCULOSIS ACTIVITY OF CLARITHROMYCIN

被引：44

作者：

LUNAHERRERA, J ^{[1
]}

REDDY, VM ^{[1
]}

DANELUZZI, D ^{[1
]}

GANGADHARAM, PRJ ^{[1
]}

机构：

[1] UNIV ILLINOIS,COLL MED,DEPT MED,MYCOBACTERIOL RES LABS,CHICAGO,IL 60612

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1995年 / 39卷 / 12期

关键词：

D O I：

10.1128/AAC.39.12.2692

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Antituberculosis activity of clarithromycin (CLA), a macrolide antibiotic, was investigated in vitro, in macrophages, and in C57BL/6 mice. CLA showed high in vitro MICs (4 to > 16 mu g/ml) for several strains of Mycobacterium tuberculosis and caused slight enhancement of activity of rifampin (RIF) against H37Rv but failed to increase the activity of either RIF or isoniazid (INH) against other strains, However, inside J774A.1 macrophages, CLA showed high activity and was synergistic with RIF against some strains of tubercle bacilli susceptible or resistant to INH and RIF. In the in vivo studies with a drug-susceptible strain (H37Rv), CLA protected mice from mortality due to tuberculosis for up to 8 weeks of observation, The CFU data for lungs and Spleens revealed that the antituberculosis activity of CLA is inferior to those of INH and streptomycin, However, the activity of CLA when used alone or in combination was comparable to that of thiacetazone, indicating its potential usefulness as a secondary drug for the treatment of tuberculosis.

引用

页码：2692 / 2695

页数：4

共 17 条

[1]

BIEHLE JR, 1993, 93RD GEN M AM SOC MI

[2]

BROWN SD, 1994, 94TH GEN M AM SOC MI

[3] SYNERGISTIC ACTIVITIES OF CLARITHROMYCIN AND ANTITUBERCULOUS DRUGS AGAINST MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS [J].

CAVALIERI, SJ ;

BIEHLE, JR ;

SANDERS, WE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1542-1545

[4] CLARITHROMYCIN AND OTHER ANTIMICROBIAL AGENTS IN THE TREATMENT OF DISSEMINATED MYCOBACTERIUM-AVIUM INFECTIONS IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].

DAUTZENBERG, B ;

SAINTMARC, T ;

MEYOHAS, MC ;

ELIASZEWITCH, M ;

HANIEZ, F ;

ROGUES, AM ;

DEWIT, S ;

COTTE, L ;

CHAUVIN, JP ;

GROSSET, J .

ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (03) :368-372

[5] ACTIVITY OF CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM INFECTION IN PATIENTS WITH ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME - A CONTROLLED CLINICAL-TRIAL [J].

DAUTZENBERG, B ;

TRUFFOT, C ;

LEGRIS, S ;

MEYOHAS, MC ;

BERLIE, HC ;

MERCAT, A ;

CHEVRET, S ;

GROSSET, J .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (03) :564-569

[6] INVITRO AND INVIVO ACTIVITIES OF CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM [J].

FERNANDES, PB ;

HARDY, DJ ;

MCDANIEL, D ;

HANSON, CW ;

SWANSON, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1531-1534

[7] PENETRATION OF CLOARITHROMYCIN INTO LUNG TISSUES FROM PATIENTS UNDERGOING LUNG RESECTION [J].

FISH, DN ;

GOTFRIED, MH ;

DANZIGER, LH ;

RODVOLD, KA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :876-878

[8] COMPARATIVE ANTIMYCOBACTERIAL ACTIVITIES OF DIFLOXACIN, TEMAFLOXACIN, ENOXACIN, PEFLOXACIN, REFERENCE FLUOROQUINOLONES, AND A NEW MACROLIDE, CLARITHROMYCIN [J].

GORZYNSKI, EA ;

GUTMAN, SI ;

ALLEN, W .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :591-592

[9] QUALITATIVE AND QUANTITATIVE DRUG-SUSCEPTIBILITY TESTS IN MYCOBACTERIOLOGY [J].

HEIFETS, L .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 137 (05) :1217-1222

[10] SYNERGISTIC EFFECTS OF ANTIMYCOBACTERIAL DRUG-COMBINATIONS ON MYCOBACTERIUM-AVIUM COMPLEX DETERMINED RADIOMETRICALLY IN LIQUID-MEDIUM [J].

HOFFNER, SE ;

SVENSON, SB ;

KALLENIUS, G .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1987, 6 (05) :530-535

← 1 2 →